PFCS
CLRB icon

Pale Fire Capital SE’s Cellectar Biosciences CLRB Stock Holding History

Pale Fire Capital SE’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-834
Closed -$53.6K – 54
2024
Q3 		$53.6K Buy
+834
New +$55K 0.01% 48

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pale Fire Capital SE's CLRB Position: Q4 2024 in Review

Pale Fire Capital SE sold out of Cellectar Biosciences (CLRB) in Q4 2024, closing a stake of 834 shares — an estimated $53.6K sold.

Pale Fire Capital SE first reported a position in CLRB in Q3 2024 and held it in 1 quarter. The position peaked at $53.6K in Q3 2024. 30 funds tracked by Wall St. Rank hold CLRB as of Q4 2024.

  • Pale Fire Capital SE reported no remaining Cellectar Biosciences position as of Q4 2024 after selling out during the quarter.
  • Pale Fire Capital SE sold 834 Cellectar Biosciences shares in Q4 2024, an estimated $53.6K.
  • Pale Fire Capital SE first reported a position in Cellectar Biosciences in Q3 2024 and held it in 1 quarter.
  • Pale Fire Capital SE's Cellectar Biosciences position peaked at $53.6K in Q3 2024.
  • 30 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2024.

Based on Pale Fire Capital SE's 13F filing for Q4 2024, filed 13 Feb 2025.